The development of CD4 binding site antibodies during HIV-1 infection.

Published

Journal Article

Broadly neutralizing antibodies to the CD4 binding site (CD4bs) of gp120 are generated by some HIV-1-infected individuals, but little is known about the prevalence and evolution of this antibody response during the course of HIV-1 infection. We analyzed the sera of 113 HIV-1 seroconverters from three cohorts for binding to a panel of gp120 core proteins and their corresponding CD4bs knockout mutants. Among sera collected between 99 and 258 weeks post-HIV-1 infection, 88% contained antibodies to the CD4bs and 47% contained antibodies to resurfaced stabilized core (RSC) probes that react preferentially with broadly neutralizing CD4bs antibodies (BNCD4), such as monoclonal antibodies (MAbs) VRC01 and VRC-CH31. Analysis of longitudinal serum samples from a subset of 18 subjects revealed that CD4bs antibodies to gp120 arose within the first 4 to 16 weeks of infection, while the development of RSC-reactive antibodies was more varied, occurring between 10 and 152 weeks post-HIV-1 infection. Despite the presence of these antibodies, serum neutralization mediated by RSC-reactive antibodies was detected in sera from only a few donors infected for more than 3 years. Thus, CD4bs antibodies that bind a VRC01-like epitope are often induced during HIV-1 infection, but the level and potency required to mediate serum neutralization may take years to develop. An improved understanding of the immunological factors associated with the development and maturation of neutralizing CD4bs antibodies during HIV-1 infection may provide insights into the requirements for eliciting this response by vaccination.

Full Text

Duke Authors

Cited Authors

  • Lynch, RM; Tran, L; Louder, MK; Schmidt, SD; Cohen, M; CHAVI 001 Clinical Team Members, ; Dersimonian, R; Euler, Z; Gray, ES; Abdool Karim, S; Kirchherr, J; Montefiori, DC; Sibeko, S; Soderberg, K; Tomaras, G; Yang, Z-Y; Nabel, GJ; Schuitemaker, H; Morris, L; Haynes, BF; Mascola, JR

Published Date

  • July 2012

Published In

Volume / Issue

  • 86 / 14

Start / End Page

  • 7588 - 7595

PubMed ID

  • 22573869

Pubmed Central ID

  • 22573869

Electronic International Standard Serial Number (EISSN)

  • 1098-5514

Digital Object Identifier (DOI)

  • 10.1128/JVI.00734-12

Language

  • eng

Conference Location

  • United States